Respuesta a «Seguridad y efectividad de la dapagliflozina con otro inhibidor del SGLT-2: ¿Qué decisión debemos tomar?» / Response to «Security and effectivity from the dapagliflozin with other inhibitor of the SGLT-2: What decision to take?»
SEMERGEN, Soc. Esp. Med. Rural Gen. (Ed. Impr.)
; 48(3): 220-222, Abr. 2022.
Article
in Spanish
| IBECS
| ID: ibc-205229
Responsible library:
ES1.1
Localization: ES15.1 - BNCS
Full text:
Available
Collection:
National databases
/
Spain
Database:
IBECS
Main subject:
Diabetes Mellitus, Type 2
/
Sodium-Glucose Transporter 2 Inhibitors
/
Hypoglycemic Agents
Limits:
Humans
Language:
Spanish
Journal:
SEMERGEN, Soc. Esp. Med. Rural Gen. (Ed. Impr.)
Year:
2022
Document type:
Article
Institution/Affiliation country:
Hospital Universitario La Paz/España
/
Unidad de Vigilancia de la Salud/España